Eintrag weiter verarbeiten
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome
Gespeichert in:
| Zeitschriftentitel: | Medical Cannabis and Cannabinoids |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Medical Cannabis and Cannabinoids, 2, 2019, 1, S. 60-64 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
S. Karger AG
|
| Schlagwörter: |
| author_facet |
Szejko, Natalia Jakubovski, Ewgeni Fremer, Carolin Müller-Vahl, Kirsten R. Szejko, Natalia Jakubovski, Ewgeni Fremer, Carolin Müller-Vahl, Kirsten R. |
|---|---|
| author |
Szejko, Natalia Jakubovski, Ewgeni Fremer, Carolin Müller-Vahl, Kirsten R. |
| spellingShingle |
Szejko, Natalia Jakubovski, Ewgeni Fremer, Carolin Müller-Vahl, Kirsten R. Medical Cannabis and Cannabinoids Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome Pharmacology (medical) Complementary and alternative medicine Pharmacology |
| author_sort |
szejko, natalia |
| spelling |
Szejko, Natalia Jakubovski, Ewgeni Fremer, Carolin Müller-Vahl, Kirsten R. 2504-3889 S. Karger AG Pharmacology (medical) Complementary and alternative medicine Pharmacology http://dx.doi.org/10.1159/000496355 <jats:p>We present the case of a 12-year-old boy diagnosed with Tourette syndrome, who was successfully treated with a combination of vaporized medicinal cannabis and oral pure tetrahydrocannabinol (THC). Due to severe motor tics resulting in insomnia, the parents – both of whom were medical doctors – decided to initiate treatment with 0.02 g vaporized cannabis (Bedrocan with a THC content of 22% and a cannabidiol content of 1%; corresponding to a dose equivalent to 4.4 mg THC) without prior consultation of a Tourette expert. This treatment resulted – according to the parents’ report – in an immediate and nearly complete remission of the tics. Due to a further increase in tics, the parents therefore decided to implement a regular treatment with a combination of vaporized medicinal cannabis (up to 0.1 g cannabis per day, varieties Bedrocan and Amnesia Haze, corresponding to 22 mg THC/day) plus orally administered oil-based THC drops (maximum daily dose = 12.5 mg THC) resulting in a marked tic reduction. During a visit in our clinic, we were able to observe the reported beneficial effects 30 min after vaporization of 0.15 g cannabis (Amnesia Haze, equivalent to 33 mg THC; in addition, 7 mg oral THC were taken at home 6 h before the visit): tics, premonitory urges, and overall impairment significantly improved according to self-ratings, parent and clinician questionnaires. Importantly, no adverse events were reported. From this single case study, it is suggested that cannabis-based medicines and their combination (such as oral THC plus vaporized medicinal cannabis) are effective and safe in the treatment of severe tics in minors with TS. However, long-term follow-up is needed to confirm the beneficial treatment effects. We want to emphasize that in this boy treatment with cannabis was initiated by the parents before a consultation in our clinic has taken place. In our opinion, treatment with cannabis-based medicine in children should be regarded as a last-line treatment, when well-established treatments have failed to improve tics.</jats:p> Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome Medical Cannabis and Cannabinoids |
| doi_str_mv |
10.1159/000496355 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDA0OTYzNTU |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDA0OTYzNTU |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
S. Karger AG, 2019 |
| imprint_str_mv |
S. Karger AG, 2019 |
| issn |
2504-3889 |
| issn_str_mv |
2504-3889 |
| language |
English |
| mega_collection |
S. Karger AG (CrossRef) |
| match_str |
szejko2019vaporizedcannabisiseffectiveandwelltoleratedinanadolescentwithtourettesyndrome |
| publishDateSort |
2019 |
| publisher |
S. Karger AG |
| recordtype |
ai |
| record_format |
ai |
| series |
Medical Cannabis and Cannabinoids |
| source_id |
49 |
| title |
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_unstemmed |
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_full |
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_fullStr |
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_full_unstemmed |
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_short |
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_sort |
vaporized cannabis is effective and well-tolerated in an adolescent with tourette syndrome |
| topic |
Pharmacology (medical) Complementary and alternative medicine Pharmacology |
| url |
http://dx.doi.org/10.1159/000496355 |
| publishDate |
2019 |
| physical |
60-64 |
| description |
<jats:p>We present the case of a 12-year-old boy diagnosed with Tourette syndrome, who was successfully treated with a combination of vaporized medicinal cannabis and oral pure tetrahydrocannabinol (THC). Due to severe motor tics resulting in insomnia, the parents – both of whom were medical doctors – decided to initiate treatment with 0.02 g vaporized cannabis (Bedrocan with a THC content of 22% and a cannabidiol content of 1%; corresponding to a dose equivalent to 4.4 mg THC) without prior consultation of a Tourette expert. This treatment resulted – according to the parents’ report – in an immediate and nearly complete remission of the tics. Due to a further increase in tics, the parents therefore decided to implement a regular treatment with a combination of vaporized medicinal cannabis (up to 0.1 g cannabis per day, varieties Bedrocan and Amnesia Haze, corresponding to 22 mg THC/day) plus orally administered oil-based THC drops (maximum daily dose = 12.5 mg THC) resulting in a marked tic reduction. During a visit in our clinic, we were able to observe the reported beneficial effects 30 min after vaporization of 0.15 g cannabis (Amnesia Haze, equivalent to 33 mg THC; in addition, 7 mg oral THC were taken at home 6 h before the visit): tics, premonitory urges, and overall impairment significantly improved according to self-ratings, parent and clinician questionnaires. Importantly, no adverse events were reported. From this single case study, it is suggested that cannabis-based medicines and their combination (such as oral THC plus vaporized medicinal cannabis) are effective and safe in the treatment of severe tics in minors with TS. However, long-term follow-up is needed to confirm the beneficial treatment effects. We want to emphasize that in this boy treatment with cannabis was initiated by the parents before a consultation in our clinic has taken place. In our opinion, treatment with cannabis-based medicine in children should be regarded as a last-line treatment, when well-established treatments have failed to improve tics.</jats:p> |
| container_issue |
1 |
| container_start_page |
60 |
| container_title |
Medical Cannabis and Cannabinoids |
| container_volume |
2 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337307518369799 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:13:46.725Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Vaporized+Cannabis+Is+Effective+and+Well-Tolerated+in+an+Adolescent+with+Tourette+Syndrome&rft.date=2019-01-25&genre=article&issn=2504-3889&volume=2&issue=1&spage=60&epage=64&pages=60-64&jtitle=Medical+Cannabis+and+Cannabinoids&atitle=Vaporized+Cannabis+Is+Effective+and+Well-Tolerated+in+an+Adolescent+with+Tourette+Syndrome&aulast=M%C3%BCller-Vahl&aufirst=Kirsten%C2%A0R.&rft_id=info%3Adoi%2F10.1159%2F000496355&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337307518369799 |
| author | Szejko, Natalia, Jakubovski, Ewgeni, Fremer, Carolin, Müller-Vahl, Kirsten R. |
| author_facet | Szejko, Natalia, Jakubovski, Ewgeni, Fremer, Carolin, Müller-Vahl, Kirsten R., Szejko, Natalia, Jakubovski, Ewgeni, Fremer, Carolin, Müller-Vahl, Kirsten R. |
| author_sort | szejko, natalia |
| container_issue | 1 |
| container_start_page | 60 |
| container_title | Medical Cannabis and Cannabinoids |
| container_volume | 2 |
| description | <jats:p>We present the case of a 12-year-old boy diagnosed with Tourette syndrome, who was successfully treated with a combination of vaporized medicinal cannabis and oral pure tetrahydrocannabinol (THC). Due to severe motor tics resulting in insomnia, the parents – both of whom were medical doctors – decided to initiate treatment with 0.02 g vaporized cannabis (Bedrocan with a THC content of 22% and a cannabidiol content of 1%; corresponding to a dose equivalent to 4.4 mg THC) without prior consultation of a Tourette expert. This treatment resulted – according to the parents’ report – in an immediate and nearly complete remission of the tics. Due to a further increase in tics, the parents therefore decided to implement a regular treatment with a combination of vaporized medicinal cannabis (up to 0.1 g cannabis per day, varieties Bedrocan and Amnesia Haze, corresponding to 22 mg THC/day) plus orally administered oil-based THC drops (maximum daily dose = 12.5 mg THC) resulting in a marked tic reduction. During a visit in our clinic, we were able to observe the reported beneficial effects 30 min after vaporization of 0.15 g cannabis (Amnesia Haze, equivalent to 33 mg THC; in addition, 7 mg oral THC were taken at home 6 h before the visit): tics, premonitory urges, and overall impairment significantly improved according to self-ratings, parent and clinician questionnaires. Importantly, no adverse events were reported. From this single case study, it is suggested that cannabis-based medicines and their combination (such as oral THC plus vaporized medicinal cannabis) are effective and safe in the treatment of severe tics in minors with TS. However, long-term follow-up is needed to confirm the beneficial treatment effects. We want to emphasize that in this boy treatment with cannabis was initiated by the parents before a consultation in our clinic has taken place. In our opinion, treatment with cannabis-based medicine in children should be regarded as a last-line treatment, when well-established treatments have failed to improve tics.</jats:p> |
| doi_str_mv | 10.1159/000496355 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDA0OTYzNTU |
| imprint | S. Karger AG, 2019 |
| imprint_str_mv | S. Karger AG, 2019 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 2504-3889 |
| issn_str_mv | 2504-3889 |
| language | English |
| last_indexed | 2024-03-01T15:13:46.725Z |
| match_str | szejko2019vaporizedcannabisiseffectiveandwelltoleratedinanadolescentwithtourettesyndrome |
| mega_collection | S. Karger AG (CrossRef) |
| physical | 60-64 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | S. Karger AG |
| record_format | ai |
| recordtype | ai |
| series | Medical Cannabis and Cannabinoids |
| source_id | 49 |
| spelling | Szejko, Natalia Jakubovski, Ewgeni Fremer, Carolin Müller-Vahl, Kirsten R. 2504-3889 S. Karger AG Pharmacology (medical) Complementary and alternative medicine Pharmacology http://dx.doi.org/10.1159/000496355 <jats:p>We present the case of a 12-year-old boy diagnosed with Tourette syndrome, who was successfully treated with a combination of vaporized medicinal cannabis and oral pure tetrahydrocannabinol (THC). Due to severe motor tics resulting in insomnia, the parents – both of whom were medical doctors – decided to initiate treatment with 0.02 g vaporized cannabis (Bedrocan with a THC content of 22% and a cannabidiol content of 1%; corresponding to a dose equivalent to 4.4 mg THC) without prior consultation of a Tourette expert. This treatment resulted – according to the parents’ report – in an immediate and nearly complete remission of the tics. Due to a further increase in tics, the parents therefore decided to implement a regular treatment with a combination of vaporized medicinal cannabis (up to 0.1 g cannabis per day, varieties Bedrocan and Amnesia Haze, corresponding to 22 mg THC/day) plus orally administered oil-based THC drops (maximum daily dose = 12.5 mg THC) resulting in a marked tic reduction. During a visit in our clinic, we were able to observe the reported beneficial effects 30 min after vaporization of 0.15 g cannabis (Amnesia Haze, equivalent to 33 mg THC; in addition, 7 mg oral THC were taken at home 6 h before the visit): tics, premonitory urges, and overall impairment significantly improved according to self-ratings, parent and clinician questionnaires. Importantly, no adverse events were reported. From this single case study, it is suggested that cannabis-based medicines and their combination (such as oral THC plus vaporized medicinal cannabis) are effective and safe in the treatment of severe tics in minors with TS. However, long-term follow-up is needed to confirm the beneficial treatment effects. We want to emphasize that in this boy treatment with cannabis was initiated by the parents before a consultation in our clinic has taken place. In our opinion, treatment with cannabis-based medicine in children should be regarded as a last-line treatment, when well-established treatments have failed to improve tics.</jats:p> Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome Medical Cannabis and Cannabinoids |
| spellingShingle | Szejko, Natalia, Jakubovski, Ewgeni, Fremer, Carolin, Müller-Vahl, Kirsten R., Medical Cannabis and Cannabinoids, Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome, Pharmacology (medical), Complementary and alternative medicine, Pharmacology |
| title | Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_full | Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_fullStr | Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_full_unstemmed | Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_short | Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| title_sort | vaporized cannabis is effective and well-tolerated in an adolescent with tourette syndrome |
| title_unstemmed | Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome |
| topic | Pharmacology (medical), Complementary and alternative medicine, Pharmacology |
| url | http://dx.doi.org/10.1159/000496355 |